DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk

Li, Jing; Chen, Yanbo; Yu, Hongyuan; Tian, Jingshen; Yuan, Fengshun; Fan, Jialong; Liu, Yupeng; Zhu, Lin; Wang, Fan; Zhao, Yong; Pang, Da

doi:10.1038/srep43011

Cited by 18 publications

(18 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study characteristics are provided in Supplementary Table S1. Of the 33 identified studies, 16 were carried out in Europe [five studies from Germany (20,22,23,26,35) and five studies from the United Kingdom (16,18,28,36,37)], nine studies were from Asian countries (17,19,21,33,(38)(39)(40)(41)(42) and three studies were from the United States (29,43,44). The majority of included studies recruited breast cancer cases from clinical settings and one study (45) was restricted to cases with family history of breast cancer.…”

Section: Study Characteristicsmentioning

confidence: 99%

Whole-Blood DNA Methylation Markers in Early Detection of Breast Cancer: A Systematic Literature Review

Guan

Ćuk

et al. 2019

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Whole-blood DNA methylation markers have been suggested as potential biomarkers for early detection of breast cancer. We conducted a systematic review of the literature on whole-blood DNA methylation markers for breast cancer detection. PubMed and ISI Web of Knowledge were searched up to May 29, 2018. Overall, 33 studies evaluating 355 markers were included. The diagnostic value of most individual markers was relatively modest, with only six markers showing sensitivity >40% at specificity >75% [only 2 (HYAL2 and S100P) were independently validated]. Although relatively strong associations (OR 0.5 or OR 2) with breast cancer were reported for 14 markers, most of them were not independently validated. Two prospective studies performed epigenome-wide association analysis and identified 276 CpG sites related to breast cancer risk, but no overlap was observed between CpGs reported from these two studies. Five studies incorporated individual markers as panels, but only two of them used a test-validation approach. In conclusion, so far detected methylation markers are insufficient for breast cancer early detection, but markers or marker-combinations may be useful for breast cancer risk stratification. Utilizing high-throughput methods of methylation quantification, future studies should focus on further mining informative methylation markers and derivation of enhanced multimaker panels with thorough external validation ideally in prospective settings. Abbreviation: ref., reference. a Model adjusted for age, family history, age at menarche, parity, menopausal status, and body mass index. b No information for model covariates adjustment. c Model adjusted for age, family history, body mass index, and physical activity. d Model adjusted for age, race, family history of breast cancer, study site, menopausal status, parity, and age at menarche. e Crude odds ratio. f Model adjusted for menopausal status, age, and weight. g Statistical significance for OR.Guan et al.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Whole-Blood DNA Methylation Markers in Early Detection of Breast Cancer: A Systematic Literature Review

Guan

Ćuk

et al. 2019

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Peripheral blood is an easily accessible source of genomic DNA that can be used to estimate DNA methylation pro les and could serve as useful non-invasive and informative biomarkers for cancer risk (5). Several studies have investigated peripheral blood DNA methylation biomarkers in different cancer types including head and neck, urothelial, breast, lung, bladder, gastric cancer, prostate and ovarian cancers (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16). Some epidemiologic studies have assessed peripheral blood DNA methylation biomarkers in CRC.…”

Section: Introductionmentioning

confidence: 99%

A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility

Onwuka

Liu

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Differential DNA methylation panel derived from peripheral blood could serve as biomarkers of CRC susceptibility. However, most of the previous studies utilized post-diagnostic blood DNA which may be markers of disease rather than susceptibility. In addition, only few studies has evaluated the predictive potential of differential DNA methylation in CRC in a prospective cohort and on a genome-wide basis. The aim of this study was to identify potential panel of DNA methylation biomarkers in peripheral blood that are associated with CRC risk and therefore serve as epigenetic biomarkers of disease susceptibility.Methods: DNA methylation profile of a nested case-control study with 166 CRC and 424 healthy normal subjects were obtained from Gene Expression Omnibus (GEO) database. The differentially methylated markers were identified by moderated t-statistics. The DNA methylation panel were constructed by stepwise logistic regression and least absolute shrinkage and selection operator in training dataset. A methylation risk score (MRS) model was constructed and the association between MRS and CRC risk assessed. Results: We identified 48 differentially methylated CpGs sites, of which 33 were hypomethylated. Of these, sixteen-CpG based MRS that was associated with CRC risk (OR = 2.68, 95% CI: 2.13, 3.38, P < 0.0001) was constructed. This association is confirmed in the testing dataset (OR = 2.02, 95% CI: 1.48, 2.74, P < 0.0001) and persisted in both males and females, younger and older subjects, short and long time-to-diagnosis. The MRS also predicted CRC with AUC 0.82 (95% CI: 0.76, 0.88), indicating high accuracy. Conclusions: Our study has identified a novel DNA methylation panel that is associated with CRC and could, if validated be useful for the prediction of CRC risk in the future.

show abstract

“…Peripheral blood is an easily accessible source of genomic DNA that can be used to estimate DNA methylation profiles and could serve as useful non-invasive and informative biomarkers for cancer risk (6). Several studies have investigated peripheral blood DNA methylation biomarkers in different cancer types including head and neck, urothelial, breast, lung, bladder, gastric cancer, prostate and ovarian cancers (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17). Some epidemiologic studies have assessed peripheral blood DNA methylation biomarkers in CRC.…”

Section: Introductionmentioning

confidence: 99%

A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility

Onwuka

Liu

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background Differential DNA methylation panel derived from peripheral blood could serve as biomarkers of CRC susceptibility. However, most of the previous studies utilized post-diagnostic blood DNA which may be markers of disease rather than susceptibility. In addition, to date no study has evaluated the predictive potential of such markers in a prospective cohort and on a genome-wide basis. The aim of this study was to identify potential panel of DNA methylation biomarkers in peripheral blood that are associated with CRC risk and therefore serve as epigenetic biomarkers of disease susceptibility. Methods DNA methylation profile of a nested case-control study with 166 CRC and 424 healthy normal subjects were obtained from Gene Expression Omnibus (GEO) database. The differentially methylated markers were identified by moderated t-statistics. The DNA methylation panel were constructed by stepwise logistic regression and least absolute shrinkage and selection operator in training dataset. A methylation risk score (MRS) model was constructed and the association between MRS and CRC risk assessed. Results We identified 48 differentially methylated CpGs sites, of which 33 were hypomethylated. Of these, sixteen-CpG based MRS that was associated with CRC risk (OR = 2.68, 95% CI: 2.13, 3.38, P < 0.0001) was constructed. This association is confirmed in the testing dataset (OR = 2.02, 95% CI: 1.48, 2.74, P < 0.0001) and persisted in both males and females, younger and older subjects, short and long time-to-diagnosis. The MRS also predicted CRC with AUC 0.82 (95% CI: 0.76, 0.88), indicating high accuracy. Conclusions Our study has identified a novel DNA methylation panel that is associated with CRC and could be-useful for the prediction of CRC risk in the future.

show abstract

DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk

Cited by 18 publications

References 64 publications

Whole-Blood DNA Methylation Markers in Early Detection of Breast Cancer: A Systematic Literature Review

Whole-Blood DNA Methylation Markers in Early Detection of Breast Cancer: A Systematic Literature Review

A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility

A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility

Contact Info

Product

Resources

About